MYDA Advisors’s CorMedix CRMD Stock Holding History

MYDA Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-150,000	Closed	-$595K	–	116
2023 Q2	$595K	Buy	+150,000	New	+$742K	0.18%	78

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

MYDA Advisors's CRMD Position: Q3 2023 in Review

MYDA Advisors sold out of CorMedix (CRMD) in Q3 2023, closing a stake of 150,000 shares — an estimated $595K sold.

MYDA Advisors first reported a position in CRMD in Q2 2023 and held it in 1 quarter. The position peaked at $595K in Q2 2023. 92 funds tracked by Wall St. Rank hold CRMD as of Q3 2023.

MYDA Advisors reported no remaining CorMedix position as of Q3 2023 after selling out during the quarter.
MYDA Advisors sold 150,000 CorMedix shares in Q3 2023, an estimated $595K.
MYDA Advisors first reported a position in CorMedix in Q2 2023 and held it in 1 quarter.
MYDA Advisors's CorMedix position peaked at $595K in Q2 2023.
92 funds tracked by Wall St. Rank held CorMedix as of Q3 2023.

Based on MYDA Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.